Lausanne, Switzerland and Copenhagen, Denmark, March 20, 2026 – ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced the appointment of Mark Altmeyer as Chairman of the Board of Directors.
Mark Altmeyer brings more than 35 years of experience as a biopharma executive and board leader across large pharma and high-growth biotech companies focusing on multiple therapeutic areas. He has deep expertise in commercialization strategy, M&A and international expansion, with a strong track record of driving growth and enterprise value in both public and private company settings. Altmeyer is recognized for fostering high-performing teams, aligning investors and management around clear value-creation priorities.
ABOUT REPRONOVO:
ReproNovo is a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health. Our team is composed of proven experts with deep experience in reproductive medicine, drug development, regulatory affairs and business development who have throughout their careers successfully brought multiple therapies to market. ReproNovo’s lead clinical compound, RPN-001 (leflutrozole), is currently being evaluated in a U.S. Phase 2 trial in men with low sperm count and low testosterone (NCT06993155). RPN-002 (nolasiban) is in development to improve embryo implantation success rates and for the management of adenomyosis. ReproNovo is financed by Jeito Capital, BNP Paribas Asset Management Alts (formerly AXA IM Alts), founding investor M Ventures, Ysios Capital and ALSA Ventures. Headquartered in Lausanne, Switzerland, the company has its primary development team in Copenhagen, Denmark and an additional development site in Barcelona, Spain, with clinical and operational team members also based in the U.S. For more information, visit the Company’s website at www.repronovo.com or follow us on LinkedIn.
CONTACT INFORMATION:
ReproNovo
Rue de Langallerie 11
1003 Lausanne, Switzerland
info@repronovo.com
MEDIA CONTACT:
MC Services AG
Brittney Sojeva
repronovo@mc-services.eu
+49 211 529 252 14
